Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CCL NASDAQ:KIN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCLCarnival$31.37-0.6%$30.10$15.07▼$32.77$36.85B2.714.88 million shs19.09 million shsKINKindred Biosciences$9.25$9.22$3.46▼$9.28$420.52M1.3840,890 shs178,496 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCLCarnival-0.02%+1.30%+11.24%+32.17%+96.88%KINKindred Biosciences0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCLCarnival$31.37-0.6%$30.10$15.07▼$32.77$36.85B2.714.88 million shs19.09 million shsKINKindred Biosciences$9.25$9.22$3.46▼$9.28$420.52M1.3840,890 shs178,496 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCLCarnival-0.02%+1.30%+11.24%+32.17%+96.88%KINKindred Biosciences0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCLCarnival 2.62Moderate Buy$30.71-2.10% DownsideKINKindred Biosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest INTO, HRN, KIN, and CCL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025CCLCarnivalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/29/2025CCLCarnivalTigress FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $38.007/23/2025CCLCarnivalBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.00 ➝ $38.007/22/2025CCLCarnivalTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.007/21/2025CCLCarnivalTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$27.00 ➝ $31.007/16/2025CCLCarnivalCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $37.006/26/2025CCLCarnivalMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$21.00 ➝ $24.006/25/2025CCLCarnivalCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$28.00 ➝ $30.006/25/2025CCLCarnivalMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$33.00 ➝ $35.006/25/2025CCLCarnivalStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$33.00 ➝ $34.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCLCarnival$25.02B1.46$3.95 per share7.94$8.02 per share3.91KINKindred Biosciences$42.16M9.97N/AN/A$1.75 per share5.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCLCarnival$1.92B$1.8516.9515.010.719.72%27.88%5.20%9/29/2025 (Estimated)KINKindred Biosciences-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/ALatest INTO, HRN, KIN, and CCL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/29/2025Q3 2025CCLCarnival$1.31N/AN/AN/AN/AN/A6/24/2025Q2 2025CCLCarnival$0.24$0.35+$0.11$0.42$6.20 billion$6.33 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCCLCarnivalN/AN/AN/AN/AN/AKINKindred BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCLCarnival2.580.340.30KINKindred Biosciences0.197.027.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCLCarnival67.19%KINKindred Biosciences66.89%Insider OwnershipCompanyInsider OwnershipCCLCarnival7.60%KINKindred Biosciences13.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCLCarnival100,0001.17 billion1.08 billionOptionableKINKindred Biosciences6345.46 millionN/AOptionableINTO, HRN, KIN, and CCL HeadlinesRecent News About These CompaniesSmall Gains Yield Big Pain: How a $2,400 Profit Triggered an SEC, FBI, and FINRA CavalryJuly 16, 2025 | jdsupra.comErnest MarioOctober 24, 2024 | centraljersey.comCDuke Flags Lowered: Ernest Mario, Founding Chair of DUHS Board of Directors, DiesOctober 23, 2024 | today.duke.eduTWhy Silicon Valley falls prey to ‘charisma distortion,’ according to investor and Google X founding member Tom ChiAugust 19, 2024 | msn.comWillow Smith announces the new release date of her first book “Black Shields Maiden”April 23, 2024 | msn.comExplosive Growth Projected in US Pet Medication Market, the Industry to Reach $17.90 Billion by 2029 - Exclusive Focus Insight Report by AriztonApril 2, 2024 | prnewswire.co.ukPTory party donor Frank Hester to be investigated for 'racist comments' by West Yorkshire PoliceMarch 22, 2024 | mirror.co.ukMNagaland Assembly passes resolution against Centre’s move to fence India-Myanmar borderMarch 2, 2024 | scroll.inSKindred Hospital East GreensboroFebruary 22, 2024 | health.usnews.comJapan's Sony terminates $10 bln Zee India mergerJanuary 22, 2024 | reuters.comEuropean Shares Edge Higher With ECB Meeting In The SpotlightJanuary 22, 2024 | markets.businessinsider.comEarnings Optimism May Contribute To Continued Strength On Wall StreetJanuary 22, 2024 | markets.businessinsider.comAuthorities investigating garage fire in KindredDecember 28, 2023 | valleynewslive.comVHonoree: Nanxi LiuDecember 17, 2023 | latimes.comStart-up Cradle tucks in $24m for protein engineering AINovember 29, 2023 | pharmaphorum.comPStartup Cradle tucks in $24m for protein engineering AINovember 29, 2023 | pharmaphorum.comPGlobal Companion Animal Pharmaceuticals Market Size To Worth USD 27.16 Billion by 2032 | CAGR of 5.7%November 8, 2023 | finance.yahoo.comMizoram Assembly elections: Incumbent MNF faces tough challenge; a look at key candidates and constituenciesNovember 6, 2023 | devdiscourse.comDMat-Su Assembly member agrees to pay $77,500 for extending property into lake and wetlandsOctober 8, 2023 | adn.comAKindred Hospital-DaytonOctober 7, 2023 | health.usnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025If Qualcomm Holds $145, Its Next Move Could Be MassiveBy Sam Quirke | August 12, 2025Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksBy Thomas Hughes | August 19, 2025Toll Brothers: A Great Buy and Hold Stock With Risks in 2025By Thomas Hughes | August 21, 2025Alphabet Reclaims $200 Threshold—Bull Run Reignited?By Ryan Hasson | August 12, 2025INTO, HRN, KIN, and CCL Company DescriptionsCarnival NYSE:CCL$31.36 -0.21 (-0.65%) Closing price 03:59 PM EasternExtended Trading$31.36 0.00 (0.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Carnival Corp. engages in the operation of cruise ships. It operates through the following business segments: North America and Australia (NAA) Cruise, Europe and Asia (EA) Cruise Operations, Cruise Support, and Tour and Others. The North America and Australia (NAA) Cruise segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe and Asia (EA) Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.Kindred Biosciences NASDAQ:KINKindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
